[{"address1": "1700 Owens Street", "address2": "Suite 205", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 660 5320", "fax": "415 525 4200", "website": "https://www.nurixtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.", "fullTimeEmployees": 286, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arthur T. Sands M.D., Ph.D.", "age": 62, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 986321, "exercisedValue": 0, "unexercisedValue": 1089996}, {"maxAge": 1, "name": "Mr. Johannes  Van Houte", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 681983, "exercisedValue": 0, "unexercisedValue": 133109}, {"maxAge": 1, "name": "Dr. Gwenn M. Hansen Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 702753, "exercisedValue": 0, "unexercisedValue": 591867}, {"maxAge": 1, "name": "Dr. John  Kuriyan Ph.D.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arthur  Weiss M.D., Ph.D.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rita  Kwong", "title": "Senior Accounting Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pasit  Phiasivongsa Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christine  Ring J.D., Ph.D.", "age": 59, "title": "Chief Legal Officer, Secretary & Chief Compliance Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 595830, "exercisedValue": 599893, "unexercisedValue": 5469113}, {"maxAge": 1, "name": "Dr. Jason  Kantor Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher B. Phelps Ph.D.", "title": "Senior VP & Head of Early Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.57, "open": 17.67, "dayLow": 17.18, "dayHigh": 18.02, "regularMarketPreviousClose": 17.57, "regularMarketOpen": 17.67, "regularMarketDayLow": 17.18, "regularMarketDayHigh": 18.02, "beta": 2.143, "forwardPE": -5.62853, "volume": 566708, "regularMarketVolume": 566708, "averageVolume": 795579, "averageVolume10days": 699320, "averageDailyVolume10Day": 699320, "bid": 17.51, "ask": 17.64, "bidSize": 100, "askSize": 100, "marketCap": 1334848768, "fiftyTwoWeekLow": 9.52, "fiftyTwoWeekHigh": 29.56, "priceToSalesTrailing12Months": 24.470636, "fiftyDayAverage": 19.6345, "twoHundredDayAverage": 20.80375, "currency": "USD", "enterpriseValue": 753569088, "floatShares": 62785717, "sharesOutstanding": 75886800, "sharesShort": 10948051, "sharesShortPriorMonth": 10793866, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1443, "heldPercentInsiders": 0.01428, "heldPercentInstitutions": 1.0779799, "shortRatio": 16.03, "shortPercentOfFloat": 0.154, "impliedSharesOutstanding": 75886800, "bookValue": 6.946, "priceToBook": 2.5323927, "lastFiscalYearEnd": 1732924800, "nextFiscalYearEnd": 1764460800, "mostRecentQuarter": 1732924800, "netIncomeToCommon": -193568992, "trailingEps": -2.88, "forwardEps": -2.78, "enterpriseToRevenue": 13.815, "enterpriseToEbitda": -3.676, "52WeekChange": 0.741328, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NRIX", "underlyingSymbol": "NRIX", "shortName": "Nurix Therapeutics, Inc.", "longName": "Nurix Therapeutics, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "961e16e7-4ed3-306e-9661-e0e70ede1cf2", "messageBoardId": "finmb_206907980", "gmtOffSetMilliseconds": -18000000, "currentPrice": 17.59, "targetHighPrice": 41.0, "targetLowPrice": 17.0, "targetMeanPrice": 32.27778, "targetMedianPrice": 35.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 609582976, "totalCashPerShare": 8.033, "ebitda": -205008992, "totalDebt": 28303000, "quickRatio": 6.375, "currentRatio": 6.462, "totalRevenue": 54549000, "debtToEquity": 5.371, "revenuePerShare": 0.813, "returnOnAssets": -0.2598, "returnOnEquity": -0.53216, "grossProfits": -167083008, "freeCashflow": -85895872, "operatingCashflow": -172584000, "revenueGrowth": -0.124, "operatingMargins": -4.86728, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]